IN8bio, Inc.

US$0.93As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:INABHealthcare
Country USA
PE (Fwd) •••
TSR 5Y CAGR (66.58%)
Div yield —
ROE (141.83%)
Biotechnology
Beta (5Y) 0.24
PE TTM —
TSR TTM (52.49%)
Mkt cap US$9.134M
ROIC (75.43%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$0.951
2.69%
(56.59%)
Hold 6|7|3|10|4
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.02
0.02
0.02
0.02
25.81%
12.80%
20.70%
26.42%
Revenue$M
0.450
0.456
0.447
0.444
11.00%
11.35%
6.58%
1.45%
Peers (US$9.134M)
Cap (US$)
PE
9.286M
—
9.170M
—
Capital
TTM
5Y
10Y
Leveragex
0.680
0.054
0.064
EBIT/Intx
0.705
0.158
0.181
Own earn%
1.50
(48.33)
(58.68)
Sh yield%
45.22
65.66
59.75
Owners
Insiders/Inst%
4.71
59.59
Short interest%
4.84
SBC / revenue%
4.33
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
15
Op margin range%
31–36
$1 testx
−0.1
Incr. ROIC%
7